Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RARE CANCER Trial: RARE 1 Nilotinib and Paclitaxel
NCT04449549Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2020
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib, Paclitaxel Micelles for Injection, sponsored by National Cancer Institute. Started Aug 2020; status: recruiting.
02
Drugs
nilotinibPaclitaxel Micelles for Injection
Beyond the preview
Go deeper on NCT04449549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04449549.